| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2136622 | Leukemia Research | 2014 | 7 Pages |
•Anti-CD40 plus anti-CD137 (BiMab) induced regression of subcutaneous MC38 tumors.•BiMab treatment of Eμ-Myc lymphoma led to significant increase in survival of mice.•Majority of mice bearing spontaneous Vk*MYC myeloma survived long-term after BiMab.
In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine if it would be successful in a mouse model of multiple myeloma. Firstly, we tested a transplantable model of disease in which multiple myeloma cells derived from Vk*MYC mice were injected intravenously. A minor proportion of anti-CD137 and BiMab treated mice experienced prolongation of life beyond 250 days. Then we tested the therapy in a spontaneously occurring multiple myeloma model, in Vk*MYC transgenic mice. The majority of mice treated survived longer than control mice, although statistical significance was not demonstrated.
